Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trialYanhang Gao, Jidong Jia, Zhansheng Jia et al.|Liver International|2020Cited by 22
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 studyRui Hua, Junqi Niu, Fei Kong et al.|Journal of Viral Hepatitis|2022Cited by 7
Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-3.5 years data updateChan Xie, Zhiliang Gao, Dong‐Ying Xie et al.|Journal of Hepatology|2022Cited by 7
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in ChinaRui Hua, Junqi Niu, Fei Kong et al.|Infectious Diseases and Therapy|2023Cited by 6
A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infectionRui Hua, Junqi Niu, Fei Kong et al.|Journal of Hepatology|2020Cited by 1